KABRA DRUGS LTD.
Latest filings
- AGM results: all 4 resolutions passed with over 99% majority · Board & Shareholder Meetings
- 37th AGM held on 30 Sep 2026; four ordinary resolutions transacted · Board & Shareholder Meetings
- Closure of Trading Window · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures and markets pharmaceutical products, with FY26 revenue from operations of ₹92.74 crore. The business expanded sharply in FY26, with revenue rising from ₹64.02 lakhs in the prior year. The company has received a Letter of Intent from the Government of Chhattisgarh to set up a pharmaceutical manufacturing facility at Nava Raipur Pharma Park, with proposed investment of ₹200 crore and around 250 direct and indirect jobs expected. It plans to launch its own generic branded formulations across South India in phases, using channel partners arranged by an external agency called 'Mr. Franchise'. The company is also entering defence manufacturing with AI integration, applying for a SCOMET License from DGFT and establishing an AI & Defence Technology R&D facility at Cactus TECCI Park in Chennai. The board has approved adding business objects covering drones and defence equipment, electric vehicle components, renewable energy, steel, hospitals, dairy, agro farms, hospitality, and AI technology, and the company has been renamed Aanjaay Industries Limited effective July 6, 2026. Trade receivables rose to ₹7,077.60 lakhs in FY26 from ₹60.05 lakhs in FY25.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from KABRA DRUGS LTD.'s filed financials and exchange disclosures
What does KABRA DRUGS LTD. do?
KABRA DRUGS LTD. is a Pharmaceuticals & Biotechnology company listed on BSE.
Is KABRA DRUGS LTD. profitable?
Yes. Over the trailing twelve months KABRA DRUGS LTD. reported a net profit of ₹4.97 Cr on revenue of ₹93 Cr.
Does KABRA DRUGS LTD. pay a dividend?
Not in the latest reported year — KABRA DRUGS LTD.'s dividend payout for FY26 was nil.
Is KABRA DRUGS LTD. debt-free?
On a net basis, yes. It reported borrowings of ₹0.43 Cr on its 31 Mar 2026 balance sheet, but holds ₹10 Cr more cash than debt.
Is KABRA DRUGS LTD. expensive compared with its peers?
On trailing P/E, KABRA DRUGS LTD. ranks 16 of 158 in Pharmaceuticals — cheaper than 90% of them, against an industry median of 31.2×. This is a position, not a valuation judgement.
How much does the KABRA DRUGS LTD. share price move in a day?
On a typical session KABRA DRUGS LTD. moves 2.10% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.
Where can I track KABRA DRUGS LTD.'s announcements?
Every NSE and BSE filing by KABRA DRUGS LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.